Aclarion Partners with Scripps Health to Enhance Pain Diagnostics

Aclarion's Groundbreaking Agreement with Scripps Health
Agreement expands access to Nociscan technology for leading spine physicians and over 3.2 million people in the greater San Diego area
Nociscan utilizes MR Spectroscopy (MRS) and Augmented Intelligence (AI) to identify sources of chronic low back pain
Aclarion, Inc. (NASDAQ: ACON, ACONW), a pioneering healthcare technology firm, has taken a monumental step by establishing a commercial agreement with a prominent healthcare provider in Southern California. This alliance significantly enhances the accessibility of the Nociscan technology to spine physicians and their patients, benefiting millions in the area.
“Each year, we see a growing number of patients suffering from chronic low back pain,” said Dr. Robert Eastlack, an orthopedic surgeon associated with this healthcare provider. “I’ve always had a strong interest in advanced diagnostics. In recent years, I've referred several patients out of state to access the Nociscan technology. Now, with it available locally, my colleagues and I can offer critical insights to our patients right here in San Diego.”
This healthcare system encompasses multiple hospitals and outpatient facilities, treating hundreds of thousands of individuals annually through a vast network of affiliated physicians. Their commitment to innovative healthcare solutions is evident in their various clinical research and medical education initiatives.
Ryan Bond, Aclarion's Chief Strategy Officer, expressed enthusiasm about this partnership. He stated, “Dr. Eastlack is a recognized leader in the community, contributing significant knowledge in the field through his research. By integrating Nociscan within their practices, they will improve patient care and participate in research that advances spinal health.”
Chronic low back pain (cLBP) is a significant health issue affecting millions globally. Remarkably, about 266 million individuals worldwide struggle with degenerative spine conditions. Aclarion’s solution, Nociscan, stands out as the first evidence-supported software as a service (SaaS) platform specifically designed to assist physicians in distinguishing between painful and non-painful discs. By objectively quantifying chemical biomarkers linked to disc pain, Nociscan provides pivotal information that enhances diagnostic accuracy.
Utilizing Nociscan alongside existing diagnostic methods offers physicians a clearer understanding of their patients’ pain sources, thus enabling them to tailor treatment strategies effectively. The implementation of this innovative technology represents a substantial advancement in managing chronic low back pain.
For further details on locating a Nociscan center or inquiries about the technology, interested parties can visit the Aclarion website or reach out directly via email for comprehensive information. Aclarion’s commitment to pioneering healthcare solutions and pain management is encapsulated within their cutting-edge offerings, aimed at improving the quality of life for those affected by chronic pain.
About Aclarion, Inc.
Aclarion is dedicated to leveraging advanced Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, and innovative augmented intelligence algorithms to enhance clinical treatments. The company addresses chronic low back pain through Nociscan, which uniquely evaluates whether lumbar discs contribute to a patient’s pain. By processing MRS data in the cloud, Aclarion’s technology optimizes the diagnostic process for enhanced patient care.
Frequently Asked Questions
What is Nociscan?
Nociscan is a pioneering SaaS platform that leverages advanced technology to help physicians identify if lumbar discs are a source of chronic low back pain.
How does the partnership with Scripps Health benefit patients?
This collaboration allows more patients in Southern California to access Nociscan technology, enhancing diagnostic capabilities and treatment options for chronic low back pain.
Who is Dr. Robert Eastlack?
Dr. Robert Eastlack is an orthopedic surgeon and a leader within the healthcare system, specializing in spine care and advanced diagnostic methods.
What are the implications of chronic low back pain globally?
Chronic low back pain affects approximately 266 million people around the world, presenting a considerable challenge in healthcare management for both patients and physicians.
How can physicians utilize Nociscan in their practices?
Physicians can integrate Nociscan within their diagnostic workflow to gain valuable insights into lumbar disc-related pain, improving treatment strategies for their patients.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.